MELBOURNE, Australia, April 29, 2016 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the completion of their new website, www.propanc.com, incorporating important new features designed to enhance the experience of the both investors and the broader public keen to understand the Company's technology, its current operations and most importantly, its vision for the future and how it relates to the field of cancer.
In particular, the Investor Relations section of the new website features immediate posting of the Company's press releases as they are issued, as well as the automated posting of SEC filings, XBRL data, Insider Section 16 filings and detailed annual as well as quarterly financial statements. Stock information data such as quotes, charts and historical prices are updated on demand with a 20-minute delay. There is also an IR calendar featuring upcoming events and media coverage as well as an up-to-date frequently asked questions section.
"We are pleased to announce our new corporate website, which has been in the planning and development phase for a number of months," said James Nathanielsz, Propanc's Chief Executive Officer. "Our Company is now moving towards a very exciting phase, as we transition our lead product, PRP, into patient trials, and plan for an up-listing onto a national exchange, so we felt it was an important time to convey the depth of our scientific knowledge by focusing on key messages which the broader public and investors can understand, whilst updating them regularly and giving them access to information in a timely manner."
Propanc engaged Equisolve to design, develop and provide ongoing management for the new website. Equisolve is the leading company delivering cutting edge communications solutions for public companies by integrating the company's corporate website and IR website on a single platform.
Mr. Nathanielsz is currently in New York, meeting with institutional investors interested to hear about the Company's latest developments and upcoming milestones, as they make significant steps towards patient trials for their lead product, PRP. Just prior to this, a scientific advice meeting was held with the Medicines and Healthcare Products Regulatory Agency (MHRA) in London, UK. Management is currently preparing minutes and expects to report the positive feedback from this meeting to the public very soon.
The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
SOURCE Propanc Health Group Corporation